Animals > Veterinary Biologics > Guidelines / Forms Veterinary Biologics Guideline 3.17EGuide for Reporting Laboratory and Field Efficacy TrialsINTRODUCTIONThese guidelines have been prepared by the Veterinary Biologics Section (VBS) in cooperation with the Biologics Evaluation Laboratory (BEL). Their function is to standardize the submission of efficacy data submitted by a manufacturer in support of a request made in Canada for a Veterinary Biological Product Licence or a Permit to Import a Veterinary Biologic. Because of the large number of biological products imported from the United States, these guidelines take into account the formats used by the Code of Federal Regulations 9 (9CFR) of the United States. Under the Canadian Health of Animals Act (64.(1)(s)) and regulations, veterinary biological products must be demonstrated by the manufacturer to be efficacious according to the label claim in the target animal species. The efficacy of a veterinary biological product is evaluated using laboratory-based vaccination-challenge trials. Field trials with natural challenge are only used to make licensing decisions, if laboratory-based disease models in the target animal species are not available for study. Products are not released for field efficacy or safety trials without the previous submission and acceptance of the following by VBS: 1) an Outline of Production, 2) a summary of purity, potency and safety test results from the experimental serial(s), and 3) data from a laboratory-based vaccination-challenge efficacy trial. Protocols for both laboratory and field efficacy trials should follow the format of these guidelines. If the efficacy trial is also to be used in support of product safety, then a description of the responses etc. used to measure safety should be included in the protocol for the efficacy trial. Copies of all efficacy trial results (trials to select dose, antigen level, adjuvant, definitive or repeated trials) relating to a veterinary biological product submission (whether or not the product was shown to be effective) should be maintained on licensed premises and be available for inspection at all times. Part I (A-L): Experimental Protocol, describing the proposed trial protocol, together with the Outline of Production should be sent for review to VBS prior to the trial, allowing a maximum of 60 days for review. The trial should not be started until Part I (A-L): Experimental Protocol has been accepted by VBS. VBS may arrange to monitor various parts of the trial. Copies of the purity, potency and laboratory safety results of the experimental serial to be used in the efficacy trial should also be sent to VBS prior to the start of the trial. Part 11 (M-O): Results and Conclusions, describing the summary, results and conclusion/discussion together with a final copy of the experimental protocol for the trial should be submitted upon completion. Protocols for both laboratory and field efficacy trials should be submitted to: Veterinary Biologics Section GENERAL REQUIREMENTSThe submission of the pre-trial efficacy protocol or data from an efficacy trial should be submitted in the following recommended format.
CANCELLATION / CHANGES
LABORATORY BIOSAFETYAll aspects of the proposed efficacy trial must meet the standards and regulations for laboratory safety described in the most current edition of the Laboratory Biosafety Guidelines (Health and Welfare Canada and Medical Research Council of Canada), relevant federal, provincial legislation and local safety authorities. The guidelines do not reference all animal pathogens. However, the manufacturer is responsible for ensuring that the appropriate containment level is used to handle the live organisms used in the efficacy trial. Laboratory Biosafety Guidelines Office of Biosafety USE OF TARGET ANIMALS IN THE EFFICACY TRIALAll aspects involved in the proposed use of animals in the efficacy trial must meet the standards and regulations for the care and maintenance of experimental animals as described by the Canadian Council on Animal Care, relevant provincial legislation and local animal care authorities. Guide to the Care and Use of Experimental Animals: Volume I and II PART I (A-L): EXPERIMENTAL PROTOCOLA. TITLE PAGEThe title page should contain the following:
B. TABLE OF CONTENTSThis section should outline the contents of the manuscript. C. PARTICIPANTSThis page should list the names, addresses, phone numbers, fax numbers, internet addresses, and the responsibilities of the principle participants in the trial. It should also include a list of the collaborators (producers, veterinarians, etc.) participating in the trial, if this is relevant. The principle participants should confirm their participation. The qualifications and experience of the key personnel should be outlined in Appendix I. D. DESCRIPTION OF DISEASE AND RATIONALE FOR VACCINATIONSummarize the scientific medical rationale for using the product under review to control or prevent a disease in the target species. This should be supported by publications in the scientific literature, and should include a brief description of the current knowledge of the disease (clinical signs, pathogenesis, epidemiology). Give only key references, and do not review the subject extensively. Appendix II should contain copies of the key papers. E. OBJECTIVE OF THE TRIALThe objective of an efficacy trial is to demonstrate that a veterinary biological product is efficacious in the target animal species, according to the label claim made by the manufacturer. Efficacy data should be established for each clinical form of a disease, each route of administration (intramuscular, subcutaneous, intranasal, etc.), and each species (bovine, porcine, canine, feline, equine, etc.) recommended in the label claim. The efficacy trial should be conducted in fully susceptible animals of the youngest age for which the product is recommended. If the youngest age recommended for vaccination is still expected to have levels of maternal antibody, then the efficacy of the product should be established in the face of the expected levels of maternal antibody. If this data is not available, labelling should indicate that the product is for the vaccination of susceptible animals of the minimum age used in the efficacy trial, and recommend re-vaccination at appropriate intervals until such animals reach an age when interfering levels of maternal antibody would no longer be present. Specific label claims concerning the onset of immunity should also be supported by acceptable efficacy data. When recommending vaccination of adults to provide passive immunization of offspring, the efficacy must be established in the offspring of a significant number of vaccinated adults. Serological data are generally not acceptable for establishing the efficacy of a product. They should only be used when reasonable data exists to demonstrate that the serological results are indicative of protection. The objectives of the trial should be described in detail. This should include: 1) a general overview, and 2) a specific description of the efficacy objectives in terms of the experimental response(s) to be measured, the times of measurement, and the methods. For many products, these are listed in the Code of Federal Regulations 9 (9CFR) of the United States. For information on products not listed here, the specific clinical signs, pathologic, serologic, and/or immunologic responses required for licensing, as well as, the time periods over which they must be measured can be obtained from VBS veterinary reviewers for each product. For example: General Objective: Specific Objective: If the efficacy trial is also to be used in support of the product safety, then this section should also include a detailed description of the safety objectives of the trial, including: 1) a general overview, and 2) a specific description of the objectives in terms of the experimental response(s) to be measured, the times of measurement, and the methods. F. EXPERIMENTAL DESIGNThis section should include the following:
G. TRIAL SCHEDULEThe trial schedule should list the key experimental days, their corresponding dates, and the event(s) which take place (arrival, acclimatization, vaccination, challenge, sampling, observations, etc.). H. DESCRIPTION OF THE TEST MATERIALSThe composition of the veterinary biological product used in the pre-license laboratory or field efficacy trial should be that of the product intended for sale. It should be one of three experimental serials produced in a licensed facility in accordance with a previously filed Outline of Production. If the experimental serials are produced on a smaller scale in a research facility, the manufacturer must establish that they represent the product which will be produced for sale in the licensed production facilities. The manufacturer is responsible for establishing the validity of the experimental serial used to demonstrate the efficacy of a product by submitting to VBS, the summary test results of the serial for purity, potency and laboratory safety as described in the Outline of Production.
I. DESCRIPTION OF THE TEST ANIMALSThis section should describe the test animals to be used in the efficacy trial. It should include the following:
The following information must be provided: the name and intended use of the experimental veterinary biological product; the name and address of the investigator responsible for the study; the estimated dates of the commencement and completion of the trial; the date of treatment or vaccination; the number of animals and their identification; and the name and address of the federally inspected slaughter house where animals would be sent for slaughter. Note that for meat animals a withdrawal time of at least 21 (or more depending on the type of adjuvant)days is required for veterinary biological products before the animals can be shipped for slaughter. Some of the immobilizing agents used for animal restraint in the different species may have longer withdrawal times. J. TARGET ANIMAL CHALLENGE MODELSummarize the scientific rationale for using this target animal challenge model to support the product efficacy. This should be supported by publications in the scientific literature, and should include a brief description of the current knowledge of the challenge model. Provide a detailed description of the materials and methods of the challenge, as well as, information on its development, and repeatability. Specifically define a successful challenge in terms of the efficacy response(s) to be measured. K. DATA COLLECTION PROCEDURES
L. STATISTICAL METHODSThis section should outline the strategy that will be used to carry out the statistical analysis to determine the efficacy and/or safety of a product. The analysis should reflect the experimental design, including the randomization scheme and the type of outcome variables measured. It should include a description of the statistical tests to be used, the groups to be compared, the response variables to be used in the comparisons, a statement of whether the scores are to be analyzed as ordinal categories or continuous variables, and the time periods over which the comparisons will be made. The statistical methods and computer software being used to carry out the calculations should be should be listed and/or referenced. PART II (M-O): RESULTS AND CONCLUSIONSPart II should include a separate title page and table of contents. If the efficacy trial is also to be used in support of product safety, then, the data for safety objectives of the trial should be reported in a separate Part III using the same sections and reporting format as described below. M. SUMMARYThe summary should describe the purpose of the efficacy trial, the basic procedures used and the main findings (specific data and their statistical significance). The main findings should be linked to the proposed label claim. N. RESULTSThe results should include:
O. CONCLUSION/DISCUSSIONThe discussion should emphasize the important aspects of the efficacy trial, and the conclusions that follow from them. Include the implications of the findings and their limitations. Link the conclusions with the proposed label claim and objectives of the efficacy trial, but avoid unqualified statements and conclusions not completely supported by the efficacy data. Do not allude to work that has not been completed. |
Top of Page |
Important Notices |